Skip to main content

Table 5 Multivariate analysis

From: Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

 

RI

NRM

LFS

OS

GRFS

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Haplo vs MSD

0.66 (0.52–0.83)

0.0004

1.9 (1.43–2.53)

< 0.0001

0.96 (0.81–1.14)

0.66

1.18 (0.96–1.43)

0.11

0.93 (0.79–1.09)

0.37

Age (per 10 years)

1.01 (0.94–1.08)

0.87

1.33 (1.21–1.47)

< 0.0001

1.1 (1.05–1.17)

0.0004

1.19 (1.12–1.27)

< 0.0001

1.11 (1.06–1.08)

< 0.0001

Ph-neg B-ALL (ref)

          

Ph-pos B-ALL

0.77 (0.63–0.95)

0.012

1.15 (0.86–1.54)

0.34

0.88 (0.75–1.14)

0.12

0.74 (0.61–0.9)

0.002

0.94 (0.82–1.08)

0.4

T-ALL

1.04 (0.85–1.26)

0.73

1.19 (0.87–1.62)

0.28

1.07 (0.91–1.26)

0.43

1.13 (0.94–1.36)

0.19

1 (0.86–1.15)

0.95

CR2 vs CR1

2.5 (2.08–3)

< 0.0001

1.98 (1.5–2.62)

< 0.0001

2.31 (1.99–2.7)

< 0.0001

2.57 (2.17–3.06)

< 0.0001

1.95 (1.69–2.24)

< 0.001

Year of HSCT

0.99 (0.95–1.03)

0.64

0.94 (0.89–1.01)

0.074

0.98 (0.94–1.01)

0.17

0.96 (0.92–1)

0.082

1 (0.97–1.03)

0.98

Female to male vs. other

0.96 (0.8–1.15)

0.65

1.22 (0.94–1.57)

0.14

1.03 (0.88–1.19)

0.73

1.13 (0.95–1.34)

0.16

1.27 (1.12–1.45)

0.0002

MAC TBI (reference)

          

MAC CT

1.32 (1.08–1.61)

0.006

1.03 (0.76–1.39)

0.87

1.22 (1.04–1.44)

0.016

1.1 (0.9–1.34)

0.34

1.05 (0.9–1.23)

0.54

RIC

1.61 (1.27–2.02)

< 0.0001

0.62 (0.43–0.88)

0.007

1.18 (0.97–1.43)

0.095

0.99 (0.79–1.24)

0.92

1.02 (0.86–1.22)

0.82

Patient CMV positive

0.96 (0.79–1.18)

0.72

1.59 (1.15–2.19)

0.005

1.12 (0.95–1.33)

0.18

1.31 (1.07–1.6)

0.009

1.13 (0.97–1.31)

0.11

Donor CMV positive

1.21 (1.99–1.49)

0.063

0.86 (0.65–1.15)

0.32

1.09 (0.92–1.29)

0.3

1.01 (0.84–1.23)

0.89

1.01 (0.87–1.16)

0.94

Center (frailty)

 

0.32

 

0.031

 

0.31

 

0.064

 

0.007

 

Acute GVHD grade II–IV

Acute GVHD grade III–IV

Chronic GVHD

Extensive chronic GVHD

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

HR (95% CI)

P

Haplo vs MSD

1.53 (1.23–1.9)

0.0002

1.54 (1.1–2.15)

0.011

0.94 (0.74–1.18)

0.58

0.61 (0.43–0.88)

0.007

Age (per 10 years)

1.03 (0.96–1.1)

0.43

1.08 (0.97–1.2)

0.15

1.11 (1.03–1.18)

0.005

0.17 (1.06–1.29)

0.002

Ph-neg B-ALL (ref)

        

Ph-pos B-ALL

0.93 (0.76–1.114)

0.49

1.15 (0.83–1.58)

0.4

0.82 (0.67–0.99)

0.041

1.03 (0.79–1.35)

0.83

T-ALL

0.88 (0.71–1.09)

0.24

0.94 (0.66–1.33)

0.73

0.84 (0.69–1.04)

0.11

0.99 (0.74–1.32)

0.94

CR2 vs CR1

1.11 (0.9–1.37)

0.31

1.34 (0.97–1.84)

0.078

1.25 (1–1.57)

0.051

1.55 (1.13–2.13)

0.006

Year of HSCT

0.96 (0.92–1)

0.053

1 (0.93–1.07)

0.96

0.96 (0.92–1)

0.044

1.04 (0.98–1.1)

0.23

Female to male vs. other

1.23 (1.02–1.47)

0.028

1.36 (1.03–1.82)

0.033

1.73 (1.46–2.05)

< 0.0001

1.98 (1.57–2.5)

< 0.0001

MAC TBI (reference)

        

MAC CT

0.82 (0.65–1.04)

0.1

1.25 (0.9–1.75)

0.19

0.78 (0.62–0.98)

0.035

0.69 (0.49–0.96)

0.03

RIC

0.78 (0.61–1.01)

0.056

0.79 (0.53–1.19)

0.26

0.81 (0.63–1.04)

0.1

0.72 (0.5–1.04)

0.078

Patient CMV positive

1.01 (0.82–1.25)

0.93

1.34 (0.94–1.91)

0.1

1.04 (0.85–1.27)

0.69

1.17 (0.89–1.54)

0.27

Donor CMV positive

1.04 (0.85–1.28)

0.69

0.78 (0.56–1.08)

0.13

1.05 (0.86–1.27)

0.63

1.01 (0.77–1.31)

0.97

Center (frailty)

 

< 0.0001

 

0.1

 

< 0.0001

 

< 0.0001

  1. RI, relapse incidence; NRM, non-relapse mortality; LFS, leukemia-free survival; OS, overall survival; GVHD, graft versus host disease; GRFS, GVHD-free/relapse-free survival; MRD, minimal residual disease; ATG, anti-thymocyte globulin; PTCy, post-transplant cyclophosphamide; RIC, reduced intensity conditioning; MAC, myeloablative conditioning; PB, peripheral blood; BM, bone marrow